D-0040-2024 Class III Terminated
FDA drug recall D-0040-2024 was initiated by Imprimis NJOF, LLC on Oct 3, 2023 and is designated Class III. Reason for recall: Subpotent: Failing Test Results for Epinephrine The recall status is terminated (terminated Mar 21, 2025). Affected quantity: 364 bags (1 mL filled in 2 mL glass amber vials; 20 vials shipped in a bag).
Recall details
- Product Type
- Drugs
- Report Date
- Oct 11, 2023
- Initiation Date
- Oct 3, 2023
- Termination Date
- Mar 21, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 364 bags (1 mL filled in 2 mL glass amber vials; 20 vials shipped in a bag)
Product description
Epinephrine-Lidocaine HCl (0.25mg/mL and 7.5mg/mL) 1mL Single Use Intraocular injection Preservative Free NDC 71384-640-01 Not for resale. Office use only. Lot: 23APR018 Date Compounded: 24APR2023 Expires on: 17APR2024. In case of adverse event contact: www.fda.gov/medwatch or (800)-FDA-1088 Imprimis NJOF, LLC. 1705 Route 46 West, Unit 6B, Ledgewood, NJ, 07852 (844) 446-6979
Reason for recall
Subpotent: Failing Test Results for Epinephrine
Distribution pattern
Nationwide
Code information
23APR018
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0040-2024
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026